Tevogen (TVGN) Total Current Liabilities (2021 - 2026)
Tevogen's (TVGN) quarterly Total Current Liabilities came in at $7.3 million in Q1 2026, down 16.64% on a YoY basis from $8.7 million in Q1 2025, and up 2.83% quarter-over-quarter from $7.1 million in Q4 2025.
Analysis
Tevogen (TVGN) Total Current Liabilities (2021 - 2026) Analysis & Trends
Tevogen (TVGN) has reported Total Current Liabilities for 6 consecutive years, with $7.3 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 16.64% year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (down 16.64% YoY), and the FY2025 full-year result was $7.1 million, down 21.83% from the prior year.
- Total Current Liabilities grew to $7.3 million in Q1 2026 per TVGN's latest filing, from $7.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $85.5 million in Q4 2023 and bottomed at $178999.0 in Q1 2022.
- Historically, Total Current Liabilities has averaged $9.8 million across 5 years, with a median of $7.1 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 24291.09% in 2023, then plunged 89.42% in 2024.
- Over 5 years, Total Current Liabilities stood at $350454.0 in 2022, then jumped by 24291.09% to $85.5 million in 2023, then slumped by 89.42% to $9.0 million in 2024, then slipped by 21.83% to $7.1 million in 2025, then gained by 2.83% to $7.3 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $7.3 million, $7.1 million, and $6.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 127.40 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 132.90 Mn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 106.85 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 403.60 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 83.35 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 80.88 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 29.35 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 502.91 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 52.53 Mn |
| 10 | Tevogen | 27.76 Mn | 27.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 7.27 Mn |
| Dec 31, 2025 | 7.07 Mn |
| Sep 30, 2025 | 6.74 Mn |
| Jun 30, 2025 | 8.08 Mn |
| Mar 31, 2025 | 8.72 Mn |
| Dec 31, 2024 | 9.04 Mn |
| Sep 30, 2024 | 10.42 Mn |
| Jun 30, 2024 | 10.61 Mn |
| Mar 31, 2024 | 8.94 Mn |
| Dec 31, 2023 | 85.48 Mn |
| Sep 30, 2023 | 1.83 Mn |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 667,074.00 |
| Dec 31, 2022 | 350,454.00 |
| Sep 30, 2022 | 281,783.00 |
| Jun 30, 2022 | 259,234.00 |
| Mar 31, 2022 | 178,999.00 |
| Dec 31, 2021 | 59,375.00 |